Navigation Links
OHK Medical Devices to Exhibit at 2013 AAOS Annual Meeting (Booth 1108) on March 20-22, 2013 in Chicago
Date:3/6/2013

Chicago, IL (PRWEB) March 06, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will be exhibiting at the 2013 AAOS Annual Meeting. The meeting will take place March 20th through the 22nd in Chicago. The company is excited to celebrate major clinical milestones and increase the presence of the growing tourniquet of choice.

In 2012, OHK Medical Devices celebrated the 500,000 application of HemaClear®. Further, it celebrated the successful launch of HemaClear® in multiple countries including Australia, France, and South Korea..

“We are very excited to showcase our tourniquet technology. The meeting provides a unique opportunity to introduce surgeons to the first innovation in the field in over a century," said Omer Inbar, VP of Sales, OHK Medical Devices. Mr. Inbar added that, “After a very strong year in 2012, we are off to a fantastic start in 2013 as HemaClear sales continue to take off; Our current expansion efforts combine creating a presence in new markets such as Latin America, Eastern Europe and Scandinavia and deepening our footprint in the existing markets in Europe and the US.”

OHK Medical Devices will be exhibiting in Hall A at the McCormick Place, booth #1108. Surgeons and industry professionals are urged to come by the booth and learn why HemaClear® is quickly becoming the global tourniquet of choice.

About HemaClear®
HemaClear® is the world’s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10498272.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
2. DiaTech Life Sciences Announces Medical Advisory Board
3. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
6. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):